R Squared Ltd Acquires Shares of 6,770 CRISPR Therapeutics AG $CRSP

R Squared Ltd acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the second quarter, Holdings Channel.com reports. The institutional investor acquired 6,770 shares of the company’s stock, valued at approximately $329,000.

A number of other hedge funds have also recently modified their holdings of CRSP. SVB Wealth LLC purchased a new position in shares of CRISPR Therapeutics in the first quarter valued at about $25,000. Costello Asset Management INC purchased a new position in shares of CRISPR Therapeutics in the first quarter valued at about $27,000. Quantbot Technologies LP increased its position in shares of CRISPR Therapeutics by 272.4% in the first quarter. Quantbot Technologies LP now owns 1,337 shares of the company’s stock valued at $45,000 after acquiring an additional 978 shares during the period. IFP Advisors Inc increased its position in shares of CRISPR Therapeutics by 24.6% in the second quarter. IFP Advisors Inc now owns 916 shares of the company’s stock valued at $45,000 after acquiring an additional 181 shares during the period. Finally, GF Fund Management CO. LTD. increased its position in shares of CRISPR Therapeutics by 22.0% in the first quarter. GF Fund Management CO. LTD. now owns 2,186 shares of the company’s stock valued at $74,000 after acquiring an additional 394 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

Insider Activity

In related news, CEO Samarth Kulkarni sold 50,895 shares of the business’s stock in a transaction dated Friday, October 17th. The shares were sold at an average price of $67.91, for a total transaction of $3,456,279.45. Following the sale, the chief executive officer owned 254,201 shares of the company’s stock, valued at $17,262,789.91. The trade was a 16.68% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel James R. Kasinger sold 1,076 shares of the business’s stock in a transaction dated Tuesday, October 14th. The stock was sold at an average price of $66.60, for a total transaction of $71,661.60. Following the sale, the general counsel directly owned 83,402 shares in the company, valued at $5,554,573.20. The trade was a 1.27% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 56,213 shares of company stock worth $3,810,458 in the last three months. 4.30% of the stock is currently owned by insiders.

CRISPR Therapeutics Price Performance

Shares of NASDAQ CRSP opened at $67.61 on Friday. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $78.48. The company’s 50-day moving average is $61.62 and its 200 day moving average is $51.27. The stock has a market capitalization of $6.15 billion, a P/E ratio of -12.45 and a beta of 1.84.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, August 4th. The company reported ($1.29) EPS for the quarter, topping the consensus estimate of ($1.47) by $0.18. CRISPR Therapeutics had a negative net margin of 1,229.43% and a negative return on equity of 20.05%. The business had revenue of $0.89 million for the quarter, compared to analyst estimates of $6.44 million. During the same quarter in the previous year, the firm posted ($1.49) earnings per share. CRISPR Therapeutics’s quarterly revenue was up 72.5% on a year-over-year basis. Research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CRSP shares. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, September 23rd. Chardan Capital restated a “buy” rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a research report on Tuesday, August 5th. Barclays boosted their price target on shares of CRISPR Therapeutics from $42.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday, August 6th. Bank of America boosted their price target on shares of CRISPR Therapeutics from $78.00 to $93.00 and gave the company a “buy” rating in a research report on Friday, October 17th. Finally, Zacks Research upgraded shares of CRISPR Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 26th. Ten analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $72.59.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.